18F-fluorothymidine radiation dosimetry in human PET imaging studies

Hubert Vesselle, John Grierson, Lanell M. Peterson, Mark Muzi, David A. Mankoff, Kenneth Krohn

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

3′-Deoxy-3′-18F-fluorothymidine (18F-FLT) is a PET imaging agent that shows promise for studying cellular proliferation in human cancers. FLT is a nucleoside analog that enters cells and is phosphorylated by human thymidine kinase 1, but the 3′ substitution prevents further incorporation into DNA. We estimated the radiation dosimetry for this tracer from data gathered in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images of 18 patients after intravenous injection of 18F-FLT. Radiation-absorbed doses were calculated using the MIRD Committee methods, taking into account variations that were based on the distribution of activities observed in the individual patients. Effective dose equivalent (EDE) was calculated using International Commission on Radiological Protection Publication 60 tissue weighting factors for the standard man and woman. Results: For a single bladder voiding at 6 h after 18F-FLT injection, the 18F-FLT EDE (mean ± SD) was 0.028 ± 0.012 mSv/MBq (103 ± 43 mrem/mCi) for a standard male patient and 0.033 ± 0.012 mSv/MBq (121 ± 43 mrem/mCi) for a standard female patient. The organ that received the highest dose was the bladder (male, 0.179 mGy/MBq [662 mrad/mCi]; female, 0.174 mGy/MBq [646 mrad/mCi]), followed by the liver (male, 0.045 mGy/MBq [167 mrad/mCi]; female, 0.064 mGy/ MBq [238 mrad/mCi]), the kidneys (male, 0.035 mGy/MBq [131 mrad/mCi]; female, 0.042 mGy/MBq [155 mrad/mCi]), and the bone marrow (male, 0.024 mGy/MBq [89 mrad/mCi]; female, 0.033 mGy/MBq [122 mrad/mCi]). Conclusion: Organ dose estimates for 18F-FLT are comparable to those associated with other commonly performed nuclear medicine tests, and the potential radiation risks associated with 18F-FLT PET imaging are within accepted limits.

Original languageEnglish (US)
Pages (from-to)1482-1488
Number of pages7
JournalJournal of Nuclear Medicine
Volume44
Issue number9
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

Radiometry
Urinary Bladder
Radiation
Nuclear Medicine
Thromboplastin
Nucleosides
Intravenous Injections
Radioactivity
Publications
alovudine
Bone Marrow
Cell Proliferation
Kidney
Injections
Liver
DNA
Neoplasms

Keywords

  • F-fluorothymidine
  • Dosimetry
  • PET

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Vesselle, H., Grierson, J., Peterson, L. M., Muzi, M., Mankoff, D. A., & Krohn, K. (2003). 18F-fluorothymidine radiation dosimetry in human PET imaging studies. Journal of Nuclear Medicine, 44(9), 1482-1488.

18F-fluorothymidine radiation dosimetry in human PET imaging studies. / Vesselle, Hubert; Grierson, John; Peterson, Lanell M.; Muzi, Mark; Mankoff, David A.; Krohn, Kenneth.

In: Journal of Nuclear Medicine, Vol. 44, No. 9, 09.2003, p. 1482-1488.

Research output: Contribution to journalArticle

Vesselle, H, Grierson, J, Peterson, LM, Muzi, M, Mankoff, DA & Krohn, K 2003, ' 18F-fluorothymidine radiation dosimetry in human PET imaging studies', Journal of Nuclear Medicine, vol. 44, no. 9, pp. 1482-1488.
Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn K. 18F-fluorothymidine radiation dosimetry in human PET imaging studies. Journal of Nuclear Medicine. 2003 Sep;44(9):1482-1488.
Vesselle, Hubert ; Grierson, John ; Peterson, Lanell M. ; Muzi, Mark ; Mankoff, David A. ; Krohn, Kenneth. / 18F-fluorothymidine radiation dosimetry in human PET imaging studies. In: Journal of Nuclear Medicine. 2003 ; Vol. 44, No. 9. pp. 1482-1488.
@article{3234d89259d642b2829893a8824ca46f,
title = "18F-fluorothymidine radiation dosimetry in human PET imaging studies",
abstract = "3′-Deoxy-3′-18F-fluorothymidine (18F-FLT) is a PET imaging agent that shows promise for studying cellular proliferation in human cancers. FLT is a nucleoside analog that enters cells and is phosphorylated by human thymidine kinase 1, but the 3′ substitution prevents further incorporation into DNA. We estimated the radiation dosimetry for this tracer from data gathered in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images of 18 patients after intravenous injection of 18F-FLT. Radiation-absorbed doses were calculated using the MIRD Committee methods, taking into account variations that were based on the distribution of activities observed in the individual patients. Effective dose equivalent (EDE) was calculated using International Commission on Radiological Protection Publication 60 tissue weighting factors for the standard man and woman. Results: For a single bladder voiding at 6 h after 18F-FLT injection, the 18F-FLT EDE (mean ± SD) was 0.028 ± 0.012 mSv/MBq (103 ± 43 mrem/mCi) for a standard male patient and 0.033 ± 0.012 mSv/MBq (121 ± 43 mrem/mCi) for a standard female patient. The organ that received the highest dose was the bladder (male, 0.179 mGy/MBq [662 mrad/mCi]; female, 0.174 mGy/MBq [646 mrad/mCi]), followed by the liver (male, 0.045 mGy/MBq [167 mrad/mCi]; female, 0.064 mGy/ MBq [238 mrad/mCi]), the kidneys (male, 0.035 mGy/MBq [131 mrad/mCi]; female, 0.042 mGy/MBq [155 mrad/mCi]), and the bone marrow (male, 0.024 mGy/MBq [89 mrad/mCi]; female, 0.033 mGy/MBq [122 mrad/mCi]). Conclusion: Organ dose estimates for 18F-FLT are comparable to those associated with other commonly performed nuclear medicine tests, and the potential radiation risks associated with 18F-FLT PET imaging are within accepted limits.",
keywords = "F-fluorothymidine, Dosimetry, PET",
author = "Hubert Vesselle and John Grierson and Peterson, {Lanell M.} and Mark Muzi and Mankoff, {David A.} and Kenneth Krohn",
year = "2003",
month = "9",
language = "English (US)",
volume = "44",
pages = "1482--1488",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - 18F-fluorothymidine radiation dosimetry in human PET imaging studies

AU - Vesselle, Hubert

AU - Grierson, John

AU - Peterson, Lanell M.

AU - Muzi, Mark

AU - Mankoff, David A.

AU - Krohn, Kenneth

PY - 2003/9

Y1 - 2003/9

N2 - 3′-Deoxy-3′-18F-fluorothymidine (18F-FLT) is a PET imaging agent that shows promise for studying cellular proliferation in human cancers. FLT is a nucleoside analog that enters cells and is phosphorylated by human thymidine kinase 1, but the 3′ substitution prevents further incorporation into DNA. We estimated the radiation dosimetry for this tracer from data gathered in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images of 18 patients after intravenous injection of 18F-FLT. Radiation-absorbed doses were calculated using the MIRD Committee methods, taking into account variations that were based on the distribution of activities observed in the individual patients. Effective dose equivalent (EDE) was calculated using International Commission on Radiological Protection Publication 60 tissue weighting factors for the standard man and woman. Results: For a single bladder voiding at 6 h after 18F-FLT injection, the 18F-FLT EDE (mean ± SD) was 0.028 ± 0.012 mSv/MBq (103 ± 43 mrem/mCi) for a standard male patient and 0.033 ± 0.012 mSv/MBq (121 ± 43 mrem/mCi) for a standard female patient. The organ that received the highest dose was the bladder (male, 0.179 mGy/MBq [662 mrad/mCi]; female, 0.174 mGy/MBq [646 mrad/mCi]), followed by the liver (male, 0.045 mGy/MBq [167 mrad/mCi]; female, 0.064 mGy/ MBq [238 mrad/mCi]), the kidneys (male, 0.035 mGy/MBq [131 mrad/mCi]; female, 0.042 mGy/MBq [155 mrad/mCi]), and the bone marrow (male, 0.024 mGy/MBq [89 mrad/mCi]; female, 0.033 mGy/MBq [122 mrad/mCi]). Conclusion: Organ dose estimates for 18F-FLT are comparable to those associated with other commonly performed nuclear medicine tests, and the potential radiation risks associated with 18F-FLT PET imaging are within accepted limits.

AB - 3′-Deoxy-3′-18F-fluorothymidine (18F-FLT) is a PET imaging agent that shows promise for studying cellular proliferation in human cancers. FLT is a nucleoside analog that enters cells and is phosphorylated by human thymidine kinase 1, but the 3′ substitution prevents further incorporation into DNA. We estimated the radiation dosimetry for this tracer from data gathered in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images of 18 patients after intravenous injection of 18F-FLT. Radiation-absorbed doses were calculated using the MIRD Committee methods, taking into account variations that were based on the distribution of activities observed in the individual patients. Effective dose equivalent (EDE) was calculated using International Commission on Radiological Protection Publication 60 tissue weighting factors for the standard man and woman. Results: For a single bladder voiding at 6 h after 18F-FLT injection, the 18F-FLT EDE (mean ± SD) was 0.028 ± 0.012 mSv/MBq (103 ± 43 mrem/mCi) for a standard male patient and 0.033 ± 0.012 mSv/MBq (121 ± 43 mrem/mCi) for a standard female patient. The organ that received the highest dose was the bladder (male, 0.179 mGy/MBq [662 mrad/mCi]; female, 0.174 mGy/MBq [646 mrad/mCi]), followed by the liver (male, 0.045 mGy/MBq [167 mrad/mCi]; female, 0.064 mGy/ MBq [238 mrad/mCi]), the kidneys (male, 0.035 mGy/MBq [131 mrad/mCi]; female, 0.042 mGy/MBq [155 mrad/mCi]), and the bone marrow (male, 0.024 mGy/MBq [89 mrad/mCi]; female, 0.033 mGy/MBq [122 mrad/mCi]). Conclusion: Organ dose estimates for 18F-FLT are comparable to those associated with other commonly performed nuclear medicine tests, and the potential radiation risks associated with 18F-FLT PET imaging are within accepted limits.

KW - F-fluorothymidine

KW - Dosimetry

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=0142243371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142243371&partnerID=8YFLogxK

M3 - Article

C2 - 12960196

AN - SCOPUS:0142243371

VL - 44

SP - 1482

EP - 1488

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -